Planning Considerations for the Introduction of pALD
A framework to support new product introduction in national health systems
Resource Library
- Oct 20, 2023
Pediatric Treatment Optimization Roadmap
- Sep 6, 2023
Pediatric DRV/r (pDRV/r) FAQs
- Sep 6, 2023
Pediatric DRV/r (pDRV/r) Product Profile
- Jun 7, 2023
2023 CHAI HIV Mid-Year Market Memo
- Jun 5, 2023
Pediatric ALD (pALD) FAQs
- May 30, 2023
pALD Product Profile
- May 24, 2023
GAP-f pALD Introduction and Rollout Planning Considerations for National Programmes
- May 4, 2023
The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
- Dec 16, 2022
2022 HIV Market Report
- May 31, 2022
2022 CHAI HIV Mid-Year Market Memo
- May 24, 2022
GAP-f pDTG Implementation Considerations for National Programmes
- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
- Mar 17, 2022
Adult DRV/r (400/50mg) Clinical Action Memo
- Mar 17, 2022
CHAI DRV/r 2L Product Profile
- Mar 17, 2022
DRV/r (400/50mg) FAQs
- Nov 16, 2021
2021 Regional HIV Market Briefs
- Oct 12, 2021
Pediatric DTG FAQs
- Oct 12, 2021
2021 HIV Market Report
- Oct 12, 2021
CHAI Pediatric DTG Product Profile